Medical News / ASH Meeting 2020, Largest Hemophilia B Gene Therapy Study to Date Hits Early Benefit, Safety Marks

The first reported phase 3 trial data for hemophilia B treated with a gene therapy show investigational agent etranacogene dezaparvovec resulted in severely ill patients being able to discontinue prophylaxis without bleeding events at 26 weeks. The Health Outcomes with Pauda Gene; Evaluation in Hemophilia B (HOPE-B) study—the largest hemophilia B gene therapy trial to date—was presented during the late-breaking abstract presentation of the American Society of Hematology (ASH) 2020 Annual Meeting this week. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Children with chronic medical conditions like sickle cell disease may spend a significant amount of time ... read more
Findings from a new study suggest there may be inherent educational biases in neurocognitive screening measures ... read more
Children with sickle cell anemia face an increased risk of intracranial and extracranial arteriopathy from as ... read more
Findings from a new study strengthen the notion that vital sign changes caused by exercise may ... read more